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and	 the	 elevated	 bile	 acid	 concentrations	 are	 associated	 with	 an	 increased	 risk	 of	 adverse	 fetal	30	
outcomes.	The	 farnesoid	X	 receptor	agonist,	obeticholic	acid	 (OCA)	 is	efficient	 in	 the	 treatment	of	31	
cholestatic	conditions	such	as	primary	biliary	cholangitis.	We	hypothesized	that	OCA	administration	32	
during	 hypercholanemic	 pregnancy	 will	 improve	 maternal	 and	 fetal	 bile	 acid	 and	 lipid	 profiles.	33	
Female	C57BL/6J	mice	were	 fed	either:	a	normal	chow	diet,	a	0.5%	cholic	acid	 (CA)-supplemented	34	
diet,	a	0.03%	OCA-supplemented	diet,	or	a	0.5%	CA	+	0.03%	OCA-supplemented	diet	for	1	week	prior	35	
to	 mating	 and	 throughout	 pregnancy	 until	 euthanization	 on	 day	 18.	 The	 effects	 of	 CA	 and	 OCA	36	
feeding	 on	maternal	 and	 fetal	morphometry,	 bile	 acid	 and	 lipid	 levels,	 and	 cecal	microbiota	were	37	
investigated.	OCA	administration	during	gestation	did	not	alter	the	maternal	or	fetal	body	weight	or	38	
organ	morphometry.	OCA	treatment	during	hypercholanemic	pregnancy	reduced	bile	acid	 levels	 in	39	
the	 fetal	 compartment.	 However,	 fetal	 dyslipidemia	 was	 not	 reversed,	 and	 OCA	 did	 not	 impact	40	
maternal	bile	acid	levels	or	dyslipidemia.	In	conclusion,	OCA	administration	during	gestation	had	no	41	
apparent	 detrimental	 impact	 on	 maternal	 or	 fetal	 morphometry	 and	 improved	 fetal	42	
hypercholanemia.	As	high	serum	bile	acid	concentrations	in	ICP	are	associated	with	increased	rates	43	








pregnancy	 (ICP).	 The	 results	 demonstrate	 that	OCA	 can	 improve	 the	 fetal	 bile	 acid	 profile.	 This	 is	50	
relevant	 not	 only	 to	women	with	 ICP,	 but	 also	 for	women	who	 become	 pregnant	while	 receiving	51	










serum	 bile	 acids.	 ICP	 is	 associated	 with	 maternal	 dyslipidemia	 (12,	 27)	 and	 increased	 risk	 of	60	
gestational	diabetes	mellitus	 (26,	 27,	 49).	 The	most	 common	 treatment	 for	 ICP	 is	ursodeoxycholic	61	




have	 been	 reported	 to	 be	 positively	 correlated	 to	 fetal	 bile	 acid	 levels,	 and	 incremental	 rises	 in	66	
maternal	serum	bile	acids	above	40	µmol/l	are	associated	with	higher	risk	of	adverse	fetal	outcomes	67	
(7,	19,	21).	The	fetal	 lipid	profile	has	also	been	shown	to	be	affected	by	maternal	cholestasis,	with	68	
increased	cholesterol	accumulation	 in	the	 fetal	 liver	and	placenta	 in	a	mouse	model	of	gestational	69	
cholestasis	and	in	the	umbilical	cord	of	neonates	exposed	to	maternal	ICP	(41).		70	
It	has	previously	been	described	that	during	normal	pregnancy,	the	activity	of	farnesoid	X	receptor	71	
(FXR),	 the	 master	 nuclear	 receptor	 regulating	 bile	 acid	 homeostasis,	 is	 decreased	 allowing	 for	 a	72	
maternal	 pro-cholestatic	 profile	 even	during	 normal	 gestation	 (31,	 33,	 39).	However,	 it	 is	 thought	73	
that	 in	 ICP,	 the	 combination	 of	 genetic	 susceptibility,	 elevated	 reproductive	 hormones	 and	74	
environmental	factors	may	lead	to	an	exacerbation	of	the	pro-cholestatic	profile	found	in	pregnancy	75	
and	result	in	a	pathological	rise	of	bile	acid	levels	(17).		76	





synthesis	 (51).	 	 Clinical	 trials	 of	 OCA	 have	 shown	 promising	 results	 for	 the	 treatment	 of	 primary	80	
biliary	cholangitis	(PBC)	and	non-alcoholic	steatohepatitis	(NASH)	(2).		81	
In	this	study,	we	used	a	previously	established	model	of	0.5%	cholic	acid	(CA)	feeding	in	pregnancy	82	









light/dark	 cycle	 with	 access	 to	 food	 and	 water	 ad	 libitum.	 All	 procedures	 were	 approved	 by	 the	90	
Animal	Welfare	and	Ethical	Review	Body	at	King’s	College	London	and	carried	out	according	to	the	91	
UK	Animals	(Scientific	Procedures)	Act	1986.	All	diets	were	supplied	by	Special	Diet	Services,	UK.	92	
We	 have	 previously	 shown	 that	 cholic	 acid	 (CA)	 feeding	 can	 induce	maternal	 hypercholanemia	 in	93	
mice	(32,	41).	Female	mice	were	assigned	to	either	standard	maintenance	and	breeding	diet	(CRM),	94	
referred	to	as	normal	chow	diet	(NC),	a	0.5%	CA-supplemented	CRM	diet,	a	0.03%	obeticholic	acid	95	






measured	 on	 days	 7,	 14	 and	 18	 of	 pregnancy	 (D7,	D14,	D18).	On	D18,	 females	were	 fasted	 for	 4	102	
hours	and	euthanized	by	CO2	inhalation.	Maternal	and	fetal	sera	were	collected	and	pup	number	per	103	
litter	 was	 assessed.	 Maternal	 liver,	 subcutaneous	 white	 adipose	 tissue	 (sWAT),	 gonadal	 white	104	
adipose	 tissue	 (gWAT),	 brown	 adipose	 tissue	 (BAT),	 fetal	 and	 placental	 weight	 were	 measured.	105	
Maternal	 liver,	 terminal	 ileum,	 fetal	 liver	 and	 placenta	 were	 collected	 and	 snap-frozen.	 Non-106	






Total	 RNA	 was	 extracted	 from	 frozen	 tissue	 samples	 using	 the	 RNeasy	 Mini	 kit	 (Qiagen,	 UK)	111	
according	to	the	manufacturer’s	guidance.	Following	RNA	extraction,	1	μg	of	total	RNA	was	reversed	112	
transcribed	using	SuperScript™	II	Reverse	Transcriptase	(Invitrogen,	UK).	RNaseOUT™	Recombinant	113	
Ribonuclease	 Inhibitor	 (Invitrogen,	 UK)	 was	 used	 as	 an	 RNase	 inhibition	 step.	 Assessment	 of	 the	114	
expression	of	 target	genes	of	 interest	was	assessed	using	quantitative	RT-PCR	with	a	ViiA™	7	Real	115	
Time	 PCR	 System	 (Thermo	 Fisher	 Scientific,	 UK)	 by	 adding	 cDNA	 in	 duplicate	 to	 a	 384-well	 plate	116	
followed	by	a	reaction	mix	of	1X	SYBR	Green	Jumpstart	Readymix	(Sigma-Aldrich,	UK)	and	1	μM	of	117	
forward/reverse	primers.	The	housekeeping	gene	cyclophilin	b	was	used	as	an	internal	reference	for	118	
quantification	 of	 relative	 gene	 expression.	 Primer	 sequences	 of	 genes	 of	 interest	 are	 provided	 in	119	






(Qiagen,	UK)	 system.	 Samples	were	 then	 centrifuged	 at	 12000	 rpm	 for	 15	minutes	 at	 4oC	 (Rotina	126	
420R	Benchtop	Centrifuge,	Hettich,	Germany).	 The	 supernatant	was	 discarded.	 The	 pellet	was	 re-127	
suspended	in	500	μL	of	lysis	buffer	containing	0.125	M	potassium	phosphate,	1	mM	EDTA	and	0.1%	128	
Triton-X	100	at	pH	7.4.	Samples	were	sonicated	at	4oC	for	8	minutes	in	a	Bioruptor	Plus	(4	cycles	of	129	
sonication	 for	 30	 seconds	 followed	 by	 4	 cycles	 of	 resting	 for	 30	 seconds).	 Samples	 were	130	
subsequently	 centrifuged	 at	 10000	 rpm	 for	 15	minutes	 at	 4oC.	 Total	 cholesterol,	 LDL-cholesterol,	131	
HDL-cholesterol,	 triglycerides	 (TGs),	 free	 fatty	 acids	 (FFAs)	 and	 total	 protein	 were	 measured	 in	132	
plasma	and	tissue	extracts	with	an	Unicel	DxC	800	autoanalyzer	(Beckman-Coulter,	the	Netherlands)	133	







Measurements	 of	 serum	 and	 cecal	 bile	 acids	 were	 performed	 on	 an	 ultra-performance	 liquid	139	
chromatography	Alliance	2695	system	coupled	to	a	Xevo	TQ	mass	spectrometer	using	a	SunFire	C18	140	
column	as	previously	described	 (1,	45).	Analytes	were	detected	using	 selected	 ion	monitoring	and	141	
quantified	 against	 deuterium-labelled	 internal	 standards.	 Quantification	 was	 achieved	 by	142	





(QIAGEN,	 UK),	 according	 to	 the	 manufacturers’	 protocol.	 Sample	 libraries	 were	 prepared	 as	148	
previously	 described	 (28)	 using	 the	 V1-V2	 primers	 (35).	 An	 Illumina	MiSeq	 platform	was	 used	 to	149	
perform	the	sequencing	with	the	MiSeq	Reagent	Kit	v3	and	paired-end	300	bp	chemistry	 (Illumina	150	
Inc,	 USA).	Mothur	 software	 (v1.35.1;	 www.mothur.org)	 was	 used	 for	 data	 analysis,	 following	 the	151	
MiSeq	 SOP	 Pipeline	 (47).	 The	 Silva	 bacterial	 database	 (www.arb-sliva.de)	were	 used	 for	 sequence	152	
alignments	and	sequences	were	classified	according	 to	 the	RDP	database	 reference	sequence	 files	153	
using	the	Wang	method	(16).	The	UniFrac	weighted	distance	matrix	created	by	Mothur	was	used	to	154	
produce	 non-metric	 multidimensional	 scaling	 (NMDS)	 plots	 and	 PERMANOVA	 (permutational	155	
multivariate	analysis	of	variance)	p-values	and	analysis	carried	out	using	the	Vegan	library	(6)	within	156	





alpha	 diversity	 (Shannon	 diversity	 index,	 H’)	 was	 calculated	 using	 Mothur	 and	 Tukey’s	 Honest	160	












We	 first	 aimed	 to	 establish	 the	 effect	 of	 hypercholanemia	 and	 OCA	 supplementation	 during	171	
pregnancy	on	body	weight	and	organ	morphometry.	During	pregnancy,	no	body	weight	differences	172	
were	 seen	 between	 groups,	 except	 on	 D7	 when	 CA	 and	 CA+OCA-fed	 females	 were	 significantly	173	
lighter	than	OCA-fed	females	(Figure	1A).	Although	no	body	weight	differences	were	registered	on	174	
D18	 gestation,	 pregnant	 females	 fed	 a	 CA	 diet	 had	 increased	 liver	 weight	 and	 decreased	 gWAT	175	
weight,	regardless	of	OCA	co-feeding	(Figure	1B).	A	trend	for	decreased	sWAT	weight	was	also	seen	176	





supplemented	 females	 on	 D18	 (Supplementary	 Fig.	 S1A,	 Private	 sharing	 link	 for	 Figshare	 data	182	
https://figshare.com/s/d95fdf67ee4829c114df).	This	weight	difference	likely	reflected	a	decrease	in	183	
gWAT,	sWAT	and	BAT	depot	weight,	despite	an	increase	in	liver	weight	(Supplementary	Fig.	S1B).		184	




We	 next	 investigated	 whether	 OCA	 administration	 ameliorated	 the	 maternal	 and	 fetal	 bile	 acid	189	
profiles	 during	 hypercholanemic	 gestation.	 In	 pregnant	 females,	 CA	 feeding	 led	 to	 a	 significant	190	
increase	 in	 total	 serum	 bile	 acid	 levels,	 CA,	 deoxycholic	 acid	 (DCA),	 taurocholic	 acid	 (TCA)	 and	191	




did	 not	 ameliorate	 total	 serum	 bile	 acid	 levels,	 although	 total	 unconjugated	 bile	 acids	 were	194	














Cecal	 bile	 acid	 concentrations	 were	 also	 measured.	 	 As	 expected	 in	 the	 cecum,	 bile	 acids	 were	209	
largely	unconjugated	(Figure	3).	Total	cecal	bile	acid	 levels	were	significantly	 increased	 in	mice	 fed	210	
CA+OCA	compared	to	CA	alone,	however	this	was	largely	due	to	enrichment	with	OCA,	and	also	with	211	
DCA	 that	 also	 increased	 in	 the	 CA-fed	 group	 (Figure	 3A,B).	Muricholic	 acids	 levels	were	markedly	212	
reduced	 in	 both	 CA	 and	 CA+OCA	 groups	 (Figure	 3B,C).	 OCA	 administration	 alone	 significantly	213	










cecal	 bacterial	 community	 was	 investigated	 by	 16S	 rRNA	 gene	 sequencing.	 Non-metric	222	
multidimensional	 scaling	 (NMDS)	 analysis	 of	 weights	 UniFrac	 distances,	 which	 shows	 how	 the	223	
microbial	 communities	 vary	between	 the	groups,	 demonstrates	 significant	differences	between	all	224	
the	 dietary	 groups	 in	 pregnant	 mice	 (Figure	 4A,	 Supplementary	 Table	 S2).	 OCA	 supplementation	225	
alone	was	the	least	different	to	NC,	with	CA	and	then	CA+OCA	being	more	dissimilar.	Differences	in	226	
the	 relative	proportion	of	phyla	were	observed	between	pregnant	 groups	 (Figure	4B);	 specifically,	227	
both	 CA	 feeding	 and	 CA+OCA	 co-feeding	 significantly	 increased	 the	 relative	 abundance	 of	228	
Proteobacteria	 in	 the	 cecum	 of	 pregnant	mice,	 compared	 to	 NC	 groups	 (Figure	 4C).	 OCA	 feeding	229	
alone	did	not	significantly	 impact	Proteobacteria,	but	 the	 relative	abundance	of	Bacteroidetes	was	230	
significantly	 decreased	 in	pregnant	 females	 (Figure	4C).	 Significant	 changes	were	 also	observed	at	231	
genus	level,	with	an	increase	in	the	relative	proportion	of	Bilophila	and	Bacteroides	 in	CA+OCA-fed	232	
mice	compared	to	all	other	groups	(Figure	4D).		This	was	reinforced	by	correlation	analysis	between	233	
microbiota	 and	 bile	 acid	 concentrations	 in	 the	 cecum,	 which	 showed	 that	 Proteobacteria	 and	234	
Bacteroidetes	 positively	 correlated	 with	 OCA,	 and	 negatively	 with	 T-OCA,	 concentrations	235	
(Supplementary	 Fig.	 S3A).	 Alpha	 diversity	 (Shannon	 diversity	 index)	 plots	 showed	 that	 CA	236	
supplementation	alone	or	co-fed	with	OCA	resulted	in	decreased	bacterial	diversity	(Supplementary	237	
Fig.	 S3B).	 Pregnancy	 caused	 a	 significant	 increase	 in	 an	 unclassified	 class	 of	 Bacteroidetes	 in	 NC	238	









during	 pregnancy,	 the	 expression	 of	 key	 genes	 for	 bile	 acid	 homeostasis	 in	 the	 liver	 and	 terminal	246	
ileum	was	investigated.	247	
The	hepatic	FXR	target	Shp	was	significantly	upregulated	in	pregnant	females	fed	a	CA	or	a	CA+OCA	248	
diet	and	 this	 change	was	concomitant	with	 the	 repression	of	hepatic	Cyp7a1	 (Figure	5A).	Both	CA	249	
and	 CA+OCA	 diet	 increased	 the	 hepatic	 expression	 of	 the	 bile	 acid	 transporters	 Bsep,	 Mrp3	 and	250	
Mrp4	in	pregnant	females	(Figure	5A).	Whilst	OCA	supplementation	alone	did	not	induce	significant	251	
hepatic	Shp	 upregulation,	Cyp7a1	 expression	was	 significantly	 decreased	 in	D18	pregnant	 females	252	
(Figure	5A).	In	parallel,	intestinal	Shp	expression	was	upregulated	in	OCA-fed	females	and	intestinal	253	
Fgf15	 expression	 was	 significantly	 increased	 by	 maternal	 CA,	 OCA	 and	 CA+OCA	 supplementation	254	
(Figure	5B).		255	
In	non-pregnant	females,	relative	mRNA	expression	followed	a	very	similar	pattern	to	pregnant	mice	256	
(Supplementary	 Fig.	 S5A,B).	 Of	 note,	 lower	 hepatic	 gene	 expression	 of	 several	 FXR	 targets	 was	257	
observed	 in	 pregnant	mice	 compared	 to	 non-pregnant,	 regardless	 of	 diet	 (Table	 1).	 Expression	 of	258	
FXR	targets	 in	the	terminal	 ileum	was	similarly	affected	by	pregnancy.	 In	pregnant	CA-fed	females,	259	
Shp	and	Fgf15	expression	was	 lower	than	outside	pregnancy	 (Table	2). Shp expression levels	were	260	
also	lower	in	CA+OCA-fed	pregnant	females	compared	to	non-pregnant (Table	2).  261	
Overall,	 we	 conclude	 that	 despite	 decreased	 expression	 of	 FXR	 target	 genes	 during	 pregnancy,	262	








CA	 feeding	alone	or	co-supplemented	with	OCA	 induced	an	upregulation	of	Shp	 expression,	and	a	269	
concomitant	 reduction	 in	Cyp7a1	and	 Ntcp,	 in	 the	 fetal	 liver	 (Figure	 6A).	Of	 note,	while	maternal	270	
OCA	diet	alone	did	not	have	an	impact	on	fetal	hepatic	Shp	expression,	a	significant	downregulation	271	
of	 hepatic	 Cyp7a1	 expression	 was	 observed,	 although	 to	 a	 lesser	 extent	 than	 in	 groups	 with	272	




acid	 transporter	 gene	 expression.	 Interestingly,	 all	 maternal	 bile	 acid	 feeding	 groups	 showed	 a	277	
significant	 upregulation	 of	 Abcg2	 expression	 in	 the	 placenta	 (Figure	 6B).	 Moreover,	 maternal	278	
CA+OCA	 feeding	 increased	 placental	Mrp2	 expression	 when	 compared	 against	 all	 other	 feeding	279	
groups,	and	Oatp1b2	expression	was	increased	compared	to	NC	and	CA	groups	(Figure	6B).	Overall,	280	




Cholestasis	 is	 commonly	 accompanied	 by	 dyslipidemia.	 Hence,	we	 next	 studied	 the	 effect	 of	OCA	285	
administration	 during	 hypercholanemic	 pregnancy	 on	maternal	 and	 fetal	 serum	 and	 hepatic	 lipid	286	
levels.	 No	 changes	 in	 total	 serum	 cholesterol	 levels	 were	 seen	 in	 pregnant	 CA	 and	 CA+OCA-287	
supplemented	 groups	 (Figure	 7A).	 However,	 females	 exposed	 to	 a	 CA	 or	 CA+OCA	 diet	 had	 raised	288	
15	
	
serum	 LDL-cholesterol	 and	decreased	HDL-cholesterol	 levels	 compared	 to	NC	 females	 (Figure	 7A),	289	
also	outside	of	pregnancy	(Supplementary	Fig.	S6A).	Conversely,	OCA	feeding	resulted	in	decreased	290	
total	 serum	 cholesterol	 levels	 compared	 to	NC	 controls	which	was	 associated	with	 a	 reduction	 in	291	
serum	HDL-cholesterol	concentrations	(Figure	7A).	Serum	HDL-cholesterol	was	also	reduced	in	non-292	
pregnant	OCA-fed	mice	(Supplementary	Fig.	S6A).	CA	feeding	did	not	alter	serum	triglyceride	levels	293	
in	 pregnant	 females,	 but	 OCA	 diet	 reduced	 serum	 triglyceride	 levels	 and	 a	 further	 decrease	 was	294	
observed	 in	CA+OCA	 fed	 females	 (Figure	7A).	 In	 contrast,	no	 significant	 changes	were	observed	 in	295	
serum	triglyceride	levels	in	non-pregnant	females	(Supplementary	Figure	S6A).	296	
In	 the	 liver,	CA,	OCA	and	CA+OCA	supplementation	of	pregnant	 females	 led	to	hepatic	cholesterol	297	
accumulation	 compared	 to	 NC	 control	 group	 (Figure	 7B).	 In	 non-pregnant	 females,	 hepatic	298	
cholesterol	 levels	 were	 significantly	 lower	 with	 OCA	 supplementation	 alone	 compared	 to	 CA	 and	299	
CA+OCA-fed	mice	(Supplementary	Fig.	S6B).		300	





fetal	 lipid	 profile.	 Maternal	 CA	 feeding	 significantly	 increased	 fetal	 serum	 cholesterol	 levels,	306	
including	 LDL-cholesterol,	 and	 this	was	 not	 altered	 by	maternal	 CA+OCA	 supplementation	 (Figure	307	
8A).	 In	 parallel,	 fetal	 serum	 HDL-cholesterol	 concentrations	 were	 reduced	 in	 maternal	 CA	 and	308	
CA+OCA	supplementation	groups.	Fetal	circulating	triglycerides	were	 increased	in	fetuses	from	CA-309	





Fetal	 hepatic	 cholesterol	 and	 FFA	 content	 were	 increased	 in	 fetuses	 from	 CA+OCA-fed	 mothers	313	
compared	 to	 NC	 mothers	 (Figure	 8B).	 However,	 maternal	 OCA	 diet	 alone	 did	 not	 affect	 fetal	314	
cholesterol	and	FFA	accumulation	in	the	liver	(Figure	8B).	A	trend	for	increased	hepatic	cholesterol	315	
and	 FFAs	was	 also	 observed	 in	 fetuses	 from	CA-fed	mothers	 compared	 to	NC	 controls,	 albeit	 not	316	
reaching	statistical	significance	(Figure	8B).	317	
To	assess	a	potential	relationship	between	fetal	and	placental	lipid	levels,	the	placental	lipid	content	318	
on	D18	of	 gestation	was	 also	 evaluated.	However,	 no	 significant	 changes	 in	 placental	 cholesterol,	319	
triglycerides	or	FFAs	content	were	registered	between	different	groups	(Figure	8C).	320	
We	 subsequently	 aimed	 to	 establish	 whether	 the	 changes	 in	 the	 fetal	 lipid	 profile	 on	 D18	 of	321	
gestation	were	due	to	shifts	in	lipid	de	novo	biosynthesis	and	transport	in	the	fetal	liver	or	placenta.	322	
Maternal	bile	acid	feeding	did	not	impact	fetal	hepatic	Hmgcr,	Fas	or	Fatp4	expression	(Figure	9A).		323	
However,	 maternal	 CA+OCA	 feeding	 led	 to	 a	 significant	 increase	 in	 placental	 expression	 of	 the	324	
cholesterol	transporter	Abca1	compared	to	NC	placentas	(Figure	9B).	Interestingly,	maternal	CA	and	325	
CA+OCA	 supplementation,	 but	 not	maternal	OCA	alone,	 resulted	 in	 a	 significant	 increase	 in	Fatp4	326	
placental	 expression	 compared	 to	 NC	 controls	 (Figure	 9B).	 Taken	 together,	 these	 data	 lead	 us	 to	327	







been	 reported	 in	 pregnancies	with	 high	maternal	 serum	 concentrations	 of	 bile	 acids	 (19,	 21,	 40),	333	
likely	related	to	fetal	exposure	to	high	bile	acid	concentrations	(7).	While	UDCA	treatment	of	ICP	has	334	
been	shown	to	reduce	maternal	bile	acid	levels	in	some	studies	(23),	it	is	not	effective	in	all	patients	335	
(8),	 and	 it	 does	not	 return	 fetal	 bile	 acid	 levels	 to	normal	 concentrations	 (20).	 	 The	present	 study	336	
shows	 that	 OCA	 administration	 in	 a	 mouse	 model	 of	 hypercholanemia,	 as	 seen	 in	 ICP,	 is	 not	337	
detrimental	to	the	mother	or	fetus	and	improves	fetal	hypercholanemia.	338	
In	our	model,	CA-feeding	 led	 to	 significantly	 raised	 total	bile	acids	 in	 fetal	 serum.	This	was	 largely	339	
due	 to	 an	 increase	 in	 taurine-conjugated	CA	and	DCA.	While	 the	 fetus	 synthesizes	bile	 acids	 from	340	
early	pregnancy	onwards,	maternal	bile	acids	can	also	cross	the	placenta	and	contribute	to	the	fetal	341	
bile	acid	pool	 (29).	Unconjugated	and,	at	much	 lower	 levels,	 taurine-conjugated	CA	and	DCA	were	342	
also	 raised	 in	 the	 serum	 of	 CA-fed	 mothers.	 In	 the	 fetal	 compartment,	 DCA	 must	 be	 maternally	343	
derived	since	the	fetus	cannot	synthesize	secondary	bile	acids	due	to	the	absence	of	gut	flora,	and	it	344	
is	 possible	 that	 CA	 is	 also	 being	 transferred	 from	 the	mother.	 However,	 it	 is	 not	 known	whether	345	
there	 is	 preferential	 transport	 of	 more	 hydrophilic	 taurine	 conjugates	 across	 the	 placenta,	 or	346	
increased	 taurine	conjugation	occurring	 in	 the	 fetal	 liver.	We	have	previously	observed	 in	humans	347	
that	 the	 ratio	 of	 conjugated	 to	 unconjugated	 bile	 acids	 is	 higher	 in	 umbilical	 cord	 blood	 than	 in	348	
maternal	serum	(20).		349	




reduced	 in	 fetuses	 from	OCA-fed	mice,	 and	 further	 reduced	 in	 both	 CA	 and	 CA+OCA-fed	 groups.	354	
18	
	
Interestingly,	OCA	 treatment	of	 hypercholanemic	mothers	was	 associated	with	 an	upregulation	of	355	
placental	 transporters	Mrp2	 (at	 the	 maternal-facing	 apical	 membrane)	 and	Oatp1b2	 (basolateral	356	
membrane),	 which	 suggests	 enhanced	 elimination	 of	 fetal	 bile	 acids	 via	 the	 placenta.	 Increased	357	
placental	 expression	 of	MRP2	 has	 previously	 been	 associated	with	 reduced	 bile	 acids	 in	 the	 fetal	358	





not	 observe	 any	detrimental	 effect	 of	OCA	on	 the	 fetus,	 in	 agreement	with	 a	 previous	 study	 that	364	





rodent	model	 reporting	 that	OCA	 treatment	 induced	 bile	 flow	 and	 hepatocyte	 expression	 of	 Shp,	370	
Bsep	 and	 Mrp-2,	 while	 repressing	 Ntcp	 and	 Cyp7a1	 expression	 (15).	 A	 more	 recent	 study	 of	371	
estrogen-induced	 cholestasis	 in	 mice	 showed	 that	 OCA	 treatment	 did	 not	 upregulate	 mRNA	372	
expression	of	FXR	targets	 in	the	 liver	or	placenta	but	did	 increase	hepatic	FXR	protein	 levels.	Total	373	
serum	bile	acid	levels	were	reduced	in	mothers,	however	serum	bile	acids	were	only	mildly	elevated	374	
in	this	model	(10).		In	contrast,	a	study	investigating	the	effect	of	OCA	administration	to	Mdr2-/-	mice	375	
found	 that	 dietary	 0.03%	 OCA	 supplementation	 failed	 to	 exert	 any	 effect	 on	 bile	 flow	 and	376	
composition.	This	study	further	reported	that	both	OCA	and	INT-767,	a	dual	FXR	and	TGR5	agonist,	377	
were	 effective	 in	 reducing	 Cyp7a1	 and	 Cyp8b1	 gene	 expression,	 but	 only	 INT-767	 administration	378	




feeding,	 this	 limited	 the	 impact	 of	OCA	 in	 our	 study.	 This	 is	 perhaps	 surprising	 given	 that	 CA	 is	 a	381	











expression	 in	 the	maternal	 liver,	 rather	 than	 via	 hepatic	 FXR	 to	modulate	 the	expression	of	 other	393	
hepatic	 genes	 involved	 in	 bile	 acid	 homeostasis.	 Our	 study	 did	 not	 assess	 the	 effect	 of	 OCA	 on	394	
markers	of	 liver	damage.	However,	we	are	aware	 that	CA	 feeding	 in	 twice	 the	dose	 in	male	Swiss	395	
Albino	 mice	 has	 previously	 been	 shown	 to	 increase	 serum	 AST,	 ALT	 and	 AP	 levels,	 as	 well	 as	396	
hepatocyte	size,	mitosis	and	necrosis	(14).		397	
Of	note,	 the	expression	of	FXR	 target	genes	was	decreased	overall	by	pregnancy,	both	 in	 the	 liver	398	
and	 terminal	 ileum,	 which	 likely	 reflects	 the	 previously	 documented	 decreased	 gestational	 FXR	399	
activity	 	 (31,	33,	39).	Nonetheless,	 in	the	 liver	of	pregnant	NC-fed	females,	OCA	administration	did	400	
not	appear	to	efficiently	overcome	the	reduction	of	FXR	activity,	and	gene	expression	levels	of	FXR	401	
targets	were	similar.	Conversely,	in	the	maternal	terminal	ileum,	the	upregulation	of	Shp	and	Fgf15	402	
expression	suggests	an	 increase	 in	FXR	activity	 induced	by	OCA	administration	to	NC-fed	mice,	but	403	
levels	 remained	 below	 those	 observed	 outside	 of	 pregnancy	 and	 so	 similarly	 indicate	 that	OCA	 is	404	




to	non-pregnant	controls	 (30).	This	highlights	the	 issue	that	 limited	efficacy	of	FXR	agonists	should	407	
be	taken	into	account	in	treatment	of	pregnant	women.			408	
OCA	was	 predominately	 unconjugated	 in	 the	 serum	 and	 the	 cecum,	 in	 contrast	 to	mice	 fed	 OCA	409	
alone	 where	 T-OCA	 predominated.	 This	 indicated	 a	 different	 pattern	 or	 activity	 of	 bile	 acid	410	
deconjugating	microbiota.	Indeed,	16S	rRNA	gene	sequencing	showed	that	there	was	an	increase	in	411	
relative	abundance	of	Bacteroidetes	and	 Proteobacteria	 (and	also	Bacteroides	 and	Bilophila,	when	412	
analysed	 at	 genus	 level)	 in	 the	 cecum	 of	 CA+OCA-fed	 females.	We	 recently	 reported	 in	 pregnant	413	
mice	 that	 bile	 salt	 hydrolase,	 involved	 in	 deconjugation	 of	 bile	 acids,	 was	 exclusively	 detected	 in	414	
Bacteroidetes,	with	Proteobacteria	also	enriched	in	pregnancy,	likely	secondary	to	increased	taurine	415	
made	 available	 after	 bile	 acid	 deconjugation	 (39).	Bilophila	Wadsworthia	 is	 known	 to	 be	 taurine-416	
metabolizing	(24).	These	findings	suggest	that	the	predominance	of	unconjugated	OCA	in	the	serum	417	
of	CA+OCA-fed	mice	could	be	due	to	an	increase	of	Bacteroidetes	and	Proteobacteria	in	the	gut.	418	
OCA	 administration	 during	 hypercholanemic	 gestation	 did	 not	 reverse	 maternal	 dyslipidemia.	 Of	419	
note,	maternal	OCA	supplementation	alone	resulted	in	a	decrease	in	serum	total	cholesterol,	due	to	420	
a	 reduction	 in	 HDL-cholesterol.	 A	 similar	 decrease	 in	 serum	 HDL-cholesterol	 was	 seen	 in	 non-421	
pregnant	 females.	 This	 decrease	 is	 not	 unexpected	 as	 OCA	 has	 previously	 been	 shown	 to	 reduce	422	
HDL-cholesterol	 in	healthy	humans,	PBC	and	NASH	patients	 (22,	37,	43),	and	we	recently	reported	423	
that	 OCA	 reduced	 serum	 cholesterol	 in	 a	 mouse	 model	 of	 gestational	 diabetes	 mellitus	 (30).	424	
Furthermore,	hepatic	cholesterol	content	was	raised	in	all	bile	acid-supplemented	mice,	although	to	425	
a	 lesser	 extent	 in	 non-pregnant	 females	 fed	 an	 OCA	 diet.	 Dyslipidemia	 with	 hepatic	 cholesterol	426	
accumulation	 has	 previously	 been	 suggested	 to	 be	 associated	 with	 Cyp7a1	 repression	 found	 in	427	
cholestasis,	 as	 downregulation	 of	 bile	 acid	 synthesis	 from	 cholesterol	 leads	 to	 cholesterol	428	





with	 previous	 studies	 showing	 that	 FXR	 activation	 reduces	 circulating	 triglycerides	 in	 db/db	 mice	432	
(52).	 Additionally,	 in	 patients	 with	 non-alcoholic	 fatty	 liver	 disease	 and	 type	 2	 diabetes,	433	
administration	 of	 50	 mg	 OCA	 daily	 for	 6	 weeks	 resulted	 in	 decreased	 serum	 triglyceride	434	
concentrations	 (34).	 However,	 OCA	 administration	 did	 not	 improve	 fetal	 dyslipidemia.	 In	 fact,	435	




bile	 acids	 observed	 in	 ICP,	 ameliorated	 fetal	 hypercholanemia	 although	 maternal	 bile	 acid	 levels	440	
were	not	significantly	decreased,	and	maternal	and	fetal	dyslipidemia	was	not	resolved.	Significantly,	441	
no	 negative	 effects	 of	 maternal	 OCA	 treatment	 on	 maternal	 and	 fetal	 morphology,	 and	 most	442	
importantly,	fetal	survival,	were	observed.	As	OCA	may	be	used	to	treat	women	of	reproductive	age	443	
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Figure	1	 –	 Effects	of	 hypercholanemia	and	OCA	 treatment	during	pregnancy	on	body	and	organ	646	
morphometry.	 (A)	Body	weight	of	pregnant	females	on	D1,	D7,	D14	and	D18.	#	P	≤	0.05	for	CA	vs	647	
OCA,	 	 *	 P	 ≤	 0.05	 for	 CA+OCA	 vs	 OCA	 groups.	 (B)	 Weight	 of	 liver,	 gonadal	 white	 adipose	 tissue	648	
(gWAT),	 subcutaneous	 white	 adipose	 tissue	 (sWAT)	 and	 brown	 adipose	 tissue	 (BAT)	 of	 pregnant	649	





Figure	 2	 –	 Effects	 of	 hypercholanemia	 and	OCA	 treatment	 during	 pregnancy	 on	 serum	bile	 acid	653	
profile.	 (A)	 Serum	 total	 bile	 acid	 (BAs),	 unconjugated	 bile	 acid,	 and	 taurine-conjugated	 bile	 acid	654	







Figure	 3	 -	 Effects	 of	 hypercholanemia	 and	 OCA	 treatment	 during	 pregnancy	 on	 cecal	 bile	 acid	660	





(A)	 	 Nonmetric	multidimensional	 scaling	 (NMDS)	 plot	 showing	 differences	 in	 bacterial	 community	666	
structure	based	on	the	weighted	UniFrac	distance	metric.	For	p-values	see	Supplementary	Table	S2.	667	
(B)	 Changes	 in	 relative	 proportion	 of	 reads	 at	 phylum	 level.	 (C	 and	 D)	 Significant	 changes	 in	 the	668	
average	relative	proportion	of	sequences	assigned	to	each	taxa	for	each	dietary	group,	at	phylum	(C)	669	







of	 genes	 regulating	 bile	 acid	 synthesis	 and	 transport	 in	 the	 liver.	 (B)	 mRNA	 expression	 of	 genes	675	
regulating	 bile	 acid	 synthesis	 and	 transport	 in	 the	 terminal	 ileum.	 Data	 are	 presented	 as	mean	 ±	676	
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Figure	 6	 -	 Expression	 of	 key	 bile	 acid	 homeostasis	 genes	 in	 the	 fetoplacental	 unit.	 (A)	 mRNA	684	
expression	 of	 genes	 regulating	 bile	 acid	 synthesis	 and	 transport	 in	 the	 fetal	 liver.	 (B)	 mRNA	685	
expression	 of	 genes	 regulating	 bile	 acid	 transport	 in	 the	 placenta.	 Data	 are	 presented	 as	mean	 ±	686	
SEM.	n	=	5-6.	*	P	≤	0.05	in	comparisons	vs	NC	and	OCA	groups.	#	P	≤	0.05	in	comparisons	vs	NC.	‡	P	≤	687	
0.05	in	comparisons	vs	all	groups.†	P	≤	0.05	in	comparisons	vs	NC	and	CA	groups.		688	
	689	
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	690	
Figure	7	–	Effects	of	hypercholanemia	and	OCA	treatment	during	pregnancy	on	serum	and	hepatic	691	
lipid	levels.		(A)	Serum	lipid	levels.	(B)	Hepatic	lipid	levels.	Data	are	presented	as	mean	±	SEM.	n	=	4-692	
6.	‡	P	≤	0.05	in	comparisons	vs	all	groups.	#	P	≤	0.05	in	comparisons	vs	NC.	*	P	≤	0.05	in	comparisons	693	
vs	NC	and	OCA	groups.	TGs,	triglycerides;	FFAs,	free	fatty	acids.	694	
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	695	
Figure	8	–	Effects	of	hypercholanemia	and	OCA	treatment	on	lipid	levels	in	the	fetoplacental	unit.	696	
(A)	Fetal	serum	lipid	levels.	(B)	Fetal	hepatic	lipid	levels.	(C)	Placental	lipid	levels.	Data	are	presented	697	
as	mean	±	SEM.	n	=	4-6.	*	P	≤	0.05	in	comparisons	vs	NC	and	OCA	groups.	#	P	≤	0.05	in	comparisons	698	
vs	NC.	$	P	≤	0.05	in	comparisons	vs	OCA	group.	TGs,	triglycerides;	FFAs,	free	fatty	acids.	699	
	700	
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	701	
Figure	9	-	Effects	of	hypercholanemia	and	OCA	treatment	on	lipid	homeostasis	genes	in	the	702	
fetoplacental	unit.	(A)	Expression	of	key	hepatic	lipid	biosynthesis	and	transport	genes	in	the	fetal	703	
liver.	(B)	Placental	expression	of	lipid	transport	genes.	Data	are	presented	as	mean	±	SEM.	n	=	4-6.	#	704	
P	≤	0.05	in	comparisons	vs	NC.	705	
